SIGN UP
LOG IN
A
09966
Alphamab Oncology
7.85
1.39+21.52%Closed16:08 05/02 HKT
OPEN/PREV CLOSE6.720/6.460
TODAY RANGE6.720-7.980
VOL6.03M
MARKET CAP7.57B
52 WEEK RANGE2.000-8.730
AVG VOL (3M)5.38M
% TURNOVER0.62%
TURNOVER45.32M
P/E (TTM)42.040
% RANGE19.50%
EPS(TTM)0.187
P/E(FORWARD)-56.638
P/B3.817
BVPS2.056
DIVIDEND--
P/S34.889
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP7.55B
SHARES OUTSTANDING964.92M
NEXT EARNINGS--
FREE FLOAT961.97M
LOT SIZE1000
EX-DIV DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·04/15 23:02
Revenues Not Telling The Story For Alphamab Oncology (HKG:9966) After Shares Rise 26%
Simply Wall St·03/27 00:03
Alphamab Oncology Full Year 2024 Earnings: Beats Expectations
Reuters·03/25 12:17
ALPHAMAB ONCOLOGY FY REVENUE RMB 640.1 MILLION
Reuters·03/25 12:17
ALPHAMAB ONCOLOGY FY NET INCOME RMB 166.3 MILLION
Simply Wall St·03/17 22:05
Exploring 3 High Growth Tech Stocks in Asia
Simply Wall St·02/28 00:39
Market Participants Recognise Alphamab Oncology's (HKG:9966) Revenues Pushing Shares 88% Higher
Simply Wall St·02/11 03:45
Even after rising 14% this past week, Alphamab Oncology (HKG:9966) shareholders are still down 78% over the past five years
Simply Wall St·12/17/2024 06:14
High Growth Tech Stocks To Watch In December 2024
Simply Wall St·12/17/2024 01:17
Breakeven On The Horizon For Alphamab Oncology (HKG:9966)
Simply Wall St·11/14/2024 23:44
After Leaping 31% Alphamab Oncology (HKG:9966) Shares Are Not Flying Under The Radar
Simply Wall St·10/20/2024 23:04
Exploring High Growth Tech Stocks In Hong Kong
Simply Wall St·08/20/2024 23:11
Alphamab Oncology First Half 2024 Earnings: CN¥0.047 loss per share (vs CN¥0.042 loss in 1H 2023)
Reuters·08/15/2024 12:41
ALPHAMAB ONCOLOGY H1 REVENUE RMB 173.6 MILLION
Same Industry
Name/Symbol
Change%
Price
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.